Sensei Biotherapeutics, Inc. (SNSE)

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation
Ask a question about Sensei Biotherapeutics, Inc. (SNSE)
Company Performance

Current Price

as of Oct 16, 2024

$0.46

P/E Ratio

N/A

Market Cap

$11.54M

Description

Sensei Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company which focuses on the discovery, development, and delivery of next generation immunotherapies for the treatment of cancer and infectious diseases. The company was founded in 1999 and is headquartered in Rockville, MD.

Metrics

Overview

  • HQRockville, MD
  • SectorHealth Technology
  • IndustryBiotechnology
  • TickerSNSE
  • Price$0.459-1.29%

Trading Information

  • Market Cap$11.54M
  • Float65.76%
  • Average Daily Volume (1m)91,581
  • Average Daily Volume (3m)57,531
  • EPS-$1.18

Company

  • RevenueN/A
  • Rev Growth (1yr)N/A
  • Net Income-$7.14M
  • Gross MarginN/A
  • EBITDA MarginN/A
  • EBITDA-$7.65M
  • EV-$31.68M
  • EV/RevenueN/A
  • P/EN/A
  • P/SN/A
  • P/B0.22
Documents
SEC Filings
8-K (2024-09-20)
8-K (2024-08-06)
8-K (2024-07-12)
8-K (2024-06-27)
8-K (2024-06-13)
8-K (2024-06-03)
8-K (2024-05-23)
8-K (2024-05-09)
8-K (2024-04-12)
8-K (2024-04-02)
8-K (2024-03-05)
8-K (2024-02-28)
8-K (2024-02-08)
8-K (2024-01-04)
8-K (2023-11-07)
8-K (2023-11-06)
8-K (2023-11-03)
8-K (2023-10-20)
8-K (2023-08-03)
8-K (2023-07-10)
8-K (2023-06-27)
8-K (2023-06-23)
8-K (2023-05-23)
8-K (2023-05-09)
8-K (2023-04-20)
8-K (2023-03-28)
8-K (2023-03-13)
8-K (2023-03-10)
8-K (2023-03-07)
8-K (2023-02-06)
10-Q (2024-08-06)
10-Q (2024-05-09)
10-Q (2023-11-07)
10-Q (2023-08-03)
10-Q (2023-05-09)
10-K (2024-02-29)
10-K (2023-03-29)
Factset Street Account
Sensei Biotherapeutics reports Q3 EPS ($0.28) vs year-ago ($0.44) ($0.76, 0.00) (2023-11-07T12:40:23Z)
Sensei Biotherapeutics reports clinical data for SNS-101 at SITC ($0.65, 0.00) (2023-11-03T20:10:08Z)
Sensei Biotherapeutics presents Trial-in-Progress Poster for Phase 1/2 clinical study of SNS-101 at ESMO 2023 ($0.64, 0.00) (2023-10-23T11:39:19Z)
Sensei Biotherapeutics holder Newtyn Management, LLC discloses 6.5% stake; issues letter conveying proposal to acquire 100% of outstanding shares - 13D ($0.69, 0.00) (2023-11-03T21:15:56Z)
Sensei Biotherapeutics discloses its board rejected $1.00/sh takeover offer from Newtyn Management - 8-K ($0.69, 0.00) (2023-11-06T11:16:14Z)